Literature DB >> 29922663

The Medical Management of Gastro-Oesophageal Reflux Disease.

Neel Sharma1, Khek Yu Ho1.   

Abstract

BACKGROUND: Gastro-oesophageal reflux disease (GORD) is a common global phenomenon. It is associated with the backflow of gastric contents proximally, typically due to transient relaxations of the lower oesophageal sphincter. Various factors contribute to GORD, including obesity, smoking, alcohol and pregnancy. The primary concern of GORD is its association with the development over time of Barrett's oesophagus and, ultimately, oesophageal adenocarcinoma.
SUMMARY: This review focuses on the various medical interventions that are useful in the treatment of GORD. KEY MESSAGES: Various lifestyle interventions such as weight loss and smoking cessation are useful in the treatment of GORD. Medical therapy relies on the use of acid suppressants such as proton pump inhibitors and histamine H2 receptor antagonists.

Entities:  

Keywords:  Barrett's oesophagus; Gastro-oesophageal reflux disease; Lifestyle interventions; Medical therapy; Oesophageal adenocarcinoma

Year:  2016        PMID: 29922663      PMCID: PMC5988163          DOI: 10.1159/000446589

Source DB:  PubMed          Journal:  Inflamm Intest Dis        ISSN: 2296-9365


  25 in total

1.  Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease.

Authors:  N T Gunaratnam; T P Jessup; J Inadomi; D P Lascewski
Journal:  Aliment Pharmacol Ther       Date:  2006-05-15       Impact factor: 8.171

2.  Body-mass index and symptoms of gastroesophageal reflux in women.

Authors:  Brian C Jacobson; Samuel C Somers; Charles S Fuchs; Ciarán P Kelly; Carlos A Camargo
Journal:  N Engl J Med       Date:  2006-06-01       Impact factor: 91.245

3.  On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis--a placebo-controlled randomized trial.

Authors:  T Lind; T Havelund; L Lundell; H Glise; K Lauritsen; S A Pedersen; O Anker-Hansen; A Stubberöd; G Eriksson; R Carlsson; O Junghard
Journal:  Aliment Pharmacol Ther       Date:  1999-07       Impact factor: 8.171

Review 4.  Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.

Authors:  B van Pinxteren; M E Numans; P A Bonis; J Lau
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

5.  Effects of posture on gastro-oesophageal reflux.

Authors:  C Stanciu; J R Bennett
Journal:  Digestion       Date:  1977-02       Impact factor: 3.216

6.  Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors.

Authors:  G H Koek; D Sifrim; T Lerut; J Janssens; J Tack
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

7.  Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation--results from two randomized controlled studies.

Authors:  P Sharma; N J Shaheen; M C Perez; B L Pilmer; M Lee; S N Atkinson; D Peura
Journal:  Aliment Pharmacol Ther       Date:  2009-04-01       Impact factor: 8.171

8.  Twenty-four-hour pH measurements in morbid obesity: effects of massive overweight, weight loss and gastric distension.

Authors:  L M Mathus-Vliegen; G N Tytgat
Journal:  Eur J Gastroenterol Hepatol       Date:  1996-07       Impact factor: 2.566

9.  Effect of baclofen on oesophageal motility and transient lower oesophageal sphincter relaxations in GORD patients: a 48-h manometric study.

Authors:  L Grossi; M Spezzaferro; L F Sacco; L Marzio
Journal:  Neurogastroenterol Motil       Date:  2008-03-27       Impact factor: 3.598

10.  A comparison of five maintenance therapies for reflux esophagitis.

Authors:  S Vigneri; R Termini; G Leandro; S Badalamenti; M Pantalena; V Savarino; F Di Mario; G Battaglia; G S Mela; A Pilotto
Journal:  N Engl J Med       Date:  1995-10-26       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.